Page 137 - TD-3-4

Tumor Discovery CTC characterization for EGFR mutations

the two previous studies. 66,67 Both these studies proposed Writing – review & editing: Micheal J. Lind, John
that the discordance in mutations between CTCs and Greenman
tumor biopsies may be due to the heterogeneity of tumors
as discussed above. The apparent discordance in mutations Ethics approval and consent to participate
observed in CTCs and tumor biopsies will need to be The study adhered to the REMARK guidelines. It was
further investigated using approaches for CTC isolation conducted at the Queens Centre for Oncology and
and downstream analysis that properly define mutations Hematology, Castle Hill Hospital, Hull, in collaboration
derived from single cells or multiple cell clones. with the Centres for Biomedicine and Clinical Sciences
5. Conclusion at the University of Hull, United Kingdom. The North
East-Newcastle & North Tyneside Local Research Ethics
The results obtained from this study suggest that the new Committee approved this study (REC13/NE/0242). In
microfluidic device described can be used to isolate CTCs accordance with the Declaration of Helsinki, informed
for downstream mutational analysis of EGFR mutations. consent was obtained in written form from all participants.
The device was able to isolate EpCAM-expressing PC-9 cell
lines and EpCAM-positive CTCs from media and blood, Consent for publication
respectively, with the isolated EpCAM-positive cells having Consent in written form was obtained from participants in
been successfully analyzed for mutations in the EGFR gene. the study to publish their data.
The mutational profile obtained from CTCs for the recruited
patients has positive clinical implications as it indicates Availability of data
that a single blood draw may be able to provide a snapshot The data from this study can be obtained on request from
of molecular events in a malignancy from initiation to
metastasis. However, the current study is limited by the the senior author, Prof J. Greenman.
sample size. Hence, it is our intention to carry out further References
studies in a larger cohort to better evaluate the utility of
this technology and make the necessary modifications for 1. Rajadurai P, Yap NY, Mohamed Yousoof SB, Cheah YK.
translation into clinical practice. Furthermore, we intend to Mutational profiling of lung cancer using next generation
analyze different methods for the genomic analysis of CTCs sequencing: A Malaysian real-world clinical diagnostic
experience. J Mol Pathol. 2023;4(1):31-43.
to define mutations in single cells.
doi: 10.3390/jmp4010004
Acknowledgments 2. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of

The authors are grateful to colleagues at the STAB VIDA, EGFR tyrosine kinase inhibitors in patients with EGFR-
Portugal for help with next-generation sequencing, mutated non-small-cell lung cancer: A meta-analysis of 13
Dr. Alex Iles (Department of Chemistry, University of randomized trials. Clin Lung Cancer. 2012;13(2):107-114.
Hull) for chip design and manufacture, and Dr. Emmanuel doi: 10.1016/j.cllc.2011.08.005
Nna of Biosystem Laboratories, Bedford, United Kingdom 3. Petrella F, Rizzo S, Attili I, et al. Stage III non-small-cell
for help with bioinformatics analysis. lung cancer: An overview of treatment options. Curr Oncol.

Funding 2023;30(3):3160-3175.
doi: 10.3390/curroncol30030239
The travel and consumable costs related to this work were
supported by the EU/Marie Curie Lung Card project 4. Robichaux JP, Le X, Vijayan RSK, et al. Structure-based
(No. 734790) and Yorkshire Cancer Research (H395). classification predicts drug response in EGFR-mutant
NSCLC. Nature. 2021;597(7878):732-737.
Conflict of interest doi: 10.1038/s41586-021-03898-1
The authors declare that they have no competing interests. 5. Sasaki A, Fujimoto Y., Inada T, et al. Efficacy of tyrosine
kinase inhibitors in patients with non-small-cell lung cancer
Author contributions with performance status 4: A case series and review of the
literature. J Med Case Rep. 202;17(1):410.
Conceptualization: John Greenman, Micheal J. Lind
Formal analysis: Nkeiruka O. Ogidi, John Greenman doi: 10.1186/s13256-023-04145-z
Investigation: Nkeiruka O. Ogidi 6. Russo A, Franchina T, Ricciardi G, Picciotto M, Adamo V.
Methodology: Nkeiruka O. Ogidi, John Greenman Heterogeneous responses to epidermal growth factor
Writing – original draft: Nkeiruka O. Ogidi receptor (EGFR) tyrosine kinase inhibitors (TKIs) in

Volume 3 Issue 4 (2024) 13 doi: 10.36922/td.3987